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Abstract
Background: Data obtained in both animal models and clinical trials suggest that cell-based therapies represent a
potential therapeutic strategy for lung repair and remodeling. Recently, new therapeutic approaches based on the
use of stem cell derivatives (e.g., conditioned medium (CM) and microvesicles (MVs)) to regenerate tissues and
improve their functions were proposed. The aim of this study was to investigate the immunomodulatory effects of
equine amniotic mesenchymal cell derivatives on lipopolysaccharide (LPS)-induced cytokine production in equine
alveolar macrophages, which may be beneficial in lung inflammatory disorders such as recurrent airway obstruction
(RAO) in horses. RAO shares many features with human asthma, including an increased number of cells expressing
mRNA for interleukin (IL)-4 and IL-5 and a decreased expression of IFN-γ in bronchoalveolar lavage fluid (BALF) of
affected horses.
Methods: The release of TNF-α, IL-6, and TGF-β1 at different time points (1, 24, 48, and 72 h) was measured in equine
alveolar macrophages stimulated or not with LPS (10 and 100 ng/mL) in the presence or absence of 10 % CM or 50 × 106
MVs/mL.
Cytokines were measured using commercially available ELISA kits. For multiple comparisons, analysis of variance was used
with Tukey post-hoc test. Differences were considered significant at p≤ 0.05.
Results: Significant modulatory effects of CM on LPS-induced TNF-α release at 24 h, and of both CM and MVs on TNF-α
release at 48 h were observed. A trend toward a modulatory effect of both CM and MVs on the release of TGF-β and
possibly IL-6 was visible over time.
Conclusions: Results support the potential use of CM and MVs in lung regenerative medicine, especially in
situations in which TGF-β may be detrimental, such as respiratory allergy. Further studies should evaluate the
potential clinical applications of CM and MVs in equine lung diseases, such as RAO and other inflammatory
disorders.
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Background
Regenerative medicine is a new therapeutic approach
based on the use of stem cells and their derivatives (e.g.
conditioned medium (CM) and microvesicles (MVs)) to
regenerate tissues and to improve their function, including
lung diseases [1–5].
Several studies have demonstrated that both mouse and
human embryonic stem cells can be induced in culture to
acquire phenotypic markers of type 2 alveolar epithelial
cells, including expression of surfactant proteins and
lamellar bodies, and formation of pseudoglandular struc-
tures. However, there are only limited available studies
concerning the effects of embryonic stem cells, or of their
derivatives, on in vivo lung pathologies [4, 5].
In parallel, other studies speculated that adult bone
marrow-derived or cord blood-derived stem cells could
engraft and differentiate in mature airway and alveolar epi-
thelial cells, vascular endothelial cells, or interstitial lung
cells. Interestingly, several recent reports suggested that
both systemic and intrapulmonary administration of bone
marrow-derived mature stem cells in mice models of acute
lung injury resulted in decreased mortality, improved
alveolar fluid clearance, and attenuated inflammation and
lung injury, despite minimal, if any, stem cell engraftment
in the lung [1]. To explain the action of mesenchymal stem
cells (MSCs), several paracrine mechanisms have been pro-
posed for bone marrow-derived stem cell effects, including
release of anti-inflammatory mediators such as interleukin
(IL)-10, angiopoietin-1, and keratinocyte growth factor
(KGF) that could modulate immune responses.
Researchers are considering other sources of stem cells
for airway tissue engineering. Extra-fetal-derived stem
cells could represent new alternative sources for lung
tissue regeneration. Indeed, recently, amniotic mesenchy-
mal cells (AMCs) isolated from human and horse term
placenta showed many characteristics of stem cells includ-
ing a very low antigenicity, no tumorigenic effects, and the
potential to differentiate into mesodermal and ectodermal
lines [6–10]. Moreover, the therapeutic use of both equine
AMCs and CM in tendon and ligament injuries in vivo
showed that the regenerative property of stem cells is
probably due either to their differentiation capacity or to
production of mediators capable of activating the intrinsic
reparative processes of damaged tissues [11]. In addition
to soluble factors present in CM, recent studies showed
that stem cells could communicate with target cells
through paracrine mechanism by means of MVs [12, 13].
Among MVs, two different populations could be identi-
fied: exosomes, which originate from invaginations of the
endosome membranes and which have a diameter between
30 and 120 nm, and the shedding vesicles that are more
heterogeneous in size (80 nm to 1 micron) and arise
directly by protrusions of the cell membrane. MVs express
different surface markers, including binding receptors to
the target cell surface. When such link occurs, the micro-
vesicle membrane merges with that of the target cell
releasing its content into the cell cytoplasm [14–16]. It was
demonstrated that MVs could be employed in vitro and in
vivo for tissue repair, increasing the degree of healing [17–
19]. In line with these findings, new studies proposed the
use of CM or purified MVs for regenerative treatment of
damaged tissues in place of stem cells.
Among equine respiratory disorders, recurrent airway
obstruction (RAO), due to its clinical aspects, is similar
to some kinds of human asthma suggesting a common
immunological basis [20]. RAO, reported as a debilitating
and incurable respiratory disease affecting stabled mature
horses worldwide, shares many features with human
asthma, including lower airway inflammation, reversible
airflow obstruction, bronchial hyper-responsiveness, mucus
accumulation, and remodeling, resulting in severe clinical
signs [21, 22]. Common clinical signs include coughing,
respiratory distress, and increased breathing effort during
periods of exacerbation, which are triggered by hypersensi-
tivity reactions to allergens and irritants mainly from hay
dust. Moreover, RAO and human severe asthma share
many structural changes such as epithelial detachment and
regeneration, goblet cell hyperplasia, and hyperplasia of the
bronchial smooth muscles, probably related to neutrophils
activity [20–22]. While the immunogenetic background of
RAO is still not completely understood, several studies
have shown that interactions of innate and adaptive
immune responses play an important role [21]. Finally, an
increased number of cells expressing mRNA for IL-4 and
IL-5 and a decreased expression of IFN-γ was demon-
strated in bronchoalveolar lavage fluid (BALf) of RAO
affected horses [23]. Some studies showed contradictory
results regarding the involvement of cytokines characteris-
tic for the Th1 or Th2 type of immune response and it has
been suggested that cytokine profiles reflecting both types
of Th responses are observed at different time points after
antigen challenge, similar to that demonstrated in human
asthma.
RAO develops over a period of years, and offers a unique
model to study the respiratory system under chronic
inflammatory conditions [22]. To date, similar to asthma,
RAO can be controlled by the administration of corticoste-
roids and bronchodilators.
The aim of the present study was to evaluate the in
vitro effect of AMC derivatives (CM and MVs) on the
production of pro- and anti-inflammatory cytokines
(tumor necrosis factor (TNF)-α, IL-6, and transforming
growth factor (TGF)-β) in equine alveolar macrophages
(AMs) collected by means of bronchoalveolar lavage
(BAL), following stimulation with lipopolysaccharide
(LPS). LPS was used according to Gupta et al. [1] and
Mei et al. [2], who demonstrated its capability for indu-
cing lung inflammation both in vivo and in vitro [3, 24].
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The study was approved by the University of Milan Ethics
Committee (Protocol Number 41/15) and informed client
consent was obtained for inclusion in the study.
Methods
Chemicals, cell culture media and supplements were ob-
tained from Sigma-Aldrich Chemical (Milan, Italy) unless
otherwise specified, and tissue culture dishes were pur-
chased from Euroclone (Milan, Italy).
Tissue collection and cell isolation
All procedures to collect allanto-amniotic membrane were
conducted following standard veterinary practice and in ac-
cordance with the 2010/63 EU directive on animal protec-
tion and Italian Law (D.L. No. 116/1992). Allanto-amniotic
membranes were obtained at term from normal pregnan-
cies of three mares and amniotic cells were obtained as de-
scribed elsewhere [10]. Amniotic cells were cultured and
expanded to passage (P)3 to obtain CM or MVs.
Preparation of CM
CM was obtained as previously described [11], pooling
the media obtained from the different amniotic samples.
Briefly, AMCs at P3 were plated into 24-well plates at a
density of 5 × 104 cells/ml/well in serum-free Dulbecco’s
modified Eagle’s medium (HG-DMEM). To generate
AMC-CM, cells were cultured for 5 days at 38.5 °C in a
humidified atmosphere of 5 % CO2. Supernatants from
each plate were then collected, pooled, centrifuged at
2500 g, and stored at –20 °C until use.
Isolation and measurement of MVs
MVs were obtained from the culture media of AMCs
derived from three different placentas, cultured for a week
with HG-DMEM supplemented with 10 % MV-deprived
fetal calf serum (FCS) and overnight in HG-DMEM
deprived of FCS and supplemented with 0.5 % BSA. The
isolation and measurement of MVs were performed as
previously described [19]. Briefly, the overnight culture
media were centrifuged at 2000 g for 20 min to remove
debris, then at 100,000 g (Beckman Coulter Optima L-
100 K ultracentrifuge) for 1 h at 4 °C, washed in serum-free
medium 199 containing N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid (HEPES) 25 mM and submitted to a
second ultracentrifugation under the same conditions. The
pellet was immediately resuspended in HG-DMEM, and a
sample of the resuspended pellet was taken for measure-
ment of MV size and concentration. The remaining part of
the pellet was cryopreserved with 1 % of dimethylsulfoxide
at –80 °C and used for the in vitro test. Size and concentra-
tion of MVs were evaluated by the Nanosight LM10 instru-
ment (Nanoparticle tracking analysis, NTA, Nano-Sight
Ltd., Amesbuty, UK), which permits discrimination of
microparticles less than 1 μm in diameter. The software
(NTA 2.0 analytic software) allows the analysis of video
images of particle movement under Brownian motion
and the calculation of diffusion coefficient, sphere
equivalent, and hydrodynamic radius of particles by
using the Strokes–Einstein equation.
Bronchoalveolar lavage fluid
BALf was obtained as previously described [25, 26] from
horses admitted to the LAHUM (Large Animal Hospital,
University of Milan) to undergo a specific diagnostic
protocol for poor performance, including airways endos-
copy and BAL. Part of the BALf, after execution of diag-
nostic procedures, was used for the in vitro study. For
cytology, an aliquot of BALf, placed in tubes with EDTA,
was centrifuged (Cytospin Rotofix 32, Hettich, Tuttlingen,
Germany) at 25 g for 5 min and stained with May Grün-
wald Giemsa for total and differential cell counts [25, 26].
The remaining aliquot of BALf was placed in plain sterile
tubes. Cells were obtained by means of centrifugation at
1200 rpm for 10 min and washed with RPMI-1640 supple-
mented with 2 mM L-glutamine, 0.1 mg/mL streptomycin,
100 IU/mL penicillin, and 5 μg/mL gentamicin. Cells were
diluted at 2 × 106/mL in the same medium. To promote
AMs adhesion, 1 mL of cell suspension was placed in 24-
well plates and incubated at 37 °C for 1 h. The adherent
cells were subsequently washed with medium to remove
the non-adherent cells. One milliliter of medium supple-
mented with 10 % FBS was added to each well in the pres-
ence or absence of LPS (obtained from Escherichia coli
serotype 0127: B810) to a final concentration of 10 and
100 ng/mL, in the presence or absence of 10 % CM, or in
the presence or absence of 50 × 106 MVs/mL.
Cells were incubated for 1, 24, 48, and 72 h. After incu-
bation, supernatants were collected by centrifugation to
remove detached cells and stored at –20 °C in 1.5-mL
tubes until the measurement of cytokines was carried out.
Measurement of cytokines
TNF-α, IL-6, and TGF-β1 measurements were made
using commercially available ELISA kits (Genorise, Glen
Mills, PA, USA) according to the manufacturer’s specifi-
cations. Results are given as pg/mL or as percentage of
relative controls.
Cellular viability
In the experiments with recombinant equine TGF-β, cell
viability was evaluated by the MTT test [27]. Briefly,
100 μL of cells were seeded in a 96-well plate and treated
in the presence or absence of equine TGF-β (300 pg/mL).
After 24-h incubation, the medium was removed and
100 μL/well of MTT solution (0.75 mg/mL) was added.
Cells were incubated for 3 h at 37 °C, the medium was dis-
carded, and cells lysed in 100 μL/well of a mixture of HCl
1N:isopropanol (1:24). The absorbance of the resulting
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solutions was read at a wavelength of 595 nm in a micro-
plate reader (EMax, Molecular Devices, Sunnyvale CA,
USA). Results are expressed as a percentage of control.
Statistical analysis
Statistical analysis was performed using GraphPad InStat
version 3.0a for Macintosh (GraphPad Software, San Diego,
CA, USA). For multiple comparisons, analysis of variance
was used with Tukey post-hoc test. Differences were con-
sidered significant at p ≤ 0.05. Results are presented as
mean ± SEM.
Results
Tissue collection and cell isolation
Cells were selected purely on their ability to adhere to
plastic. The initial viability of AMCs was >90 %. Amniotic
cells (Fig. 1a) displayed typical fibroblast-like morphology.
AMCs observed at the early stages of culture were orga-
nized as three-dimensional clusters (Fig. 1b). Molecular
biology analyses at P3 showed that these AMCs display a
typical mesenchymal stromal phenotype, with the expres-
sion of markers such as CD29, CD44, CD106, CD105, and
MHCI, but not CD34 and MHCII. Moreover, AMCs
showed differentiative potential in mesenchymal (osteo-
genic, adipogenic, and chondrogenic) and ectodermic lines
(neurogenic) as reported by Lange-Consiglio et al. [10].
Isolation and measurement of MVs
In all samples, the viability of AMCs at the time of MV
collection was 99 % as detected by Trypan blue exclu-
sion. The size of MVs ranged from 50 nm to 670 nm,
with a mean size of 258 ± 55 nm for the three samples.
The number of MVs ranged from 800 to 4700 particles/
cell, with a mean value of 2550 ± 71 particles/cell (corre-
sponding to 540 × 106 particles/mL of medium). From
this result, 10 % of CM contains about 50 × 106 MVs
and this dose of MVs was used in our experiments. This
dose was chosen on the base of a dose-response curve
studied on others target cells where this amount corre-
sponded to the higher uptake of labeled MVs [19].
Transmission electron microscopy analysis [19] re-
vealed the presence of variably sized extra-cellular mem-
branous vesicles budding from, or lying near, the cell of
origin (Fig. 1c, d). The size of MVs ranged from 100 nm
to 1000 nm, with a predominance of vesicles between
100 and 200 nm. Because of size and morphological
characteristics, the vesicles observed were mainly con-
sidered as shedding vesicles.
Cytology of BALf
Total and differential cell counts, reported as the mean
of five samples ± SEM, are shown in Table 1. Approxi-
mately 29.2 ± 3.1 × 106 AMs were isolated from each of
the five horses. Cell viability on the day of harvesting
was >95 % as assessed by Trypan blue exclusion.
Fig. 1 Cell morphology. a Monolayer of cells in first culture. b Fibroblast-like cells organized in cluster. Scale bars= 20 μm. Magnification 20×. Electron
microscopy analysis of MVs; arrows in c and d show the release of MVs from the surface of AMCs. Scale bars= 200 nm for (c) and 500 nm for (d)
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Characterization of cytokine release in equine alveolar
macrophages
AMs were selected by their ability to adhere to plastic.
After 1 h, non-adherent cells were removed and AMs
were stimulated with LPS (10 and 100 ng/mL) for 1, 24,
48, and 72 h. Results concerning the release over time
of anti-inflammatory (TGF-β) and pro-inflammatory
cytokines (TNF-α and IL-6) are reported in Fig. 2. Re-
sults are expressed as the mean of a minimum of four
experiments ± SEM.
Significant differences (p < 0.05) were observed for
TNF-α and TGF-β. Although the maximum concentration
of IL-6 appears at 24 h and gradually decreases in the fol-
lowing observation periods, no significant differences were
found compared to controls.
Characterization of the immunomodulatory effects of CM
and MVs
The ability of CM and MVs to modulate LPS-induced
cytokine production was then investigated. AMs were
treated with LPS (100 ng/mL) in the presence or absence
of CM or MVs for 1, 24, 48, and 72 h. Results (shown in
Fig. 3) are presented as the mean of a minimum of three
experiments ± SEM, and values expressed as a percent-
age of cytokine release compared to their respective
control.
Significant differences (p < 0.05) were found for the
modulatory effect of CM on LPS-induced TNF-α release
at 24 h. Additionally, significant differences were ob-
served for the modulatory capacity of CM and MVs on
TNF-α release at 48 h. Furthermore, a trend toward a
modulatory effect of CM and MVs on the release of
TGF-β and possibly IL-6 was visible over time which,
however, did not reach a statistical significance.
Effect of TGF-β and neutralizing anti-TGF-β antibody on
LPS-induced TNF-α production
In AMs treated with CM and MVs alone, a trend toward a
higher release of TGF-β compared to controls was ob-
served (Fig. 4a); at 24 h the mean values were 240 pg/mL
for the control, 371 pg/mL for CM, and 343 pg/mL for
MVs. Although these differences were not statistically sig-
nificant (p > 0.05), in light of the anti-inflammatory effects
of this cytokine in different experimental models the pos-
sible modulatory role of TGF-β on the observed effects
was investigated. Two different experiments were set up.
First, we investigated whether equine TGF-β could modu-
late LPS-induced TNF-α release and, second, we used a
neutralizing antibody to block TGF-β. The results ob-
tained were somewhat unexpected.
In Fig. 4b, the results concerning the effect of TGF-β
on TNF-α production induced by LPS stimulation are
shown. Cells were treated for 24 h in the presence or
absence of TGF-β (300 pg/mL) and LPS (100 ng/mL).
The concentration of TGF-β was chosen according to
the mean of TGF-β measured in culture supernatants. A
significant reduction (p < 0.01) in cell viability was
observed in cells treated with TGF-β compared to con-
trols together with a significant increase in TNF-α re-
lease (p < 0.01), indicative of a pro-inflammatory effect
of TGF-β in AMs under resting conditions. In contrast,
a statistically significant reduction in TNF-α release in
cells treated with TGF-β + LPS was observed (p < 0.01),
which may be explained by TGF-β-induced cytotoxicity.
The effects on TNF-α release when cells were treated
in the presence or absence of anti-TGF-β antibody
(0.2 μg/mL), control mouse IgG (0.2 μg/mL), or CM and
MVs, or LPS (100 ng/mL) for 24 h are presented in
Fig. 4c. The modulatory effects of CM and MVs on LPS-
induced TNF-α release in the groups of cells treated
with mouse IgG were confirmed. The neutralization of
TGF-β resulted in a statistically significant reduction in
LPS-induced TNF-α release, consistent with the pro-
inflammatory effect of TGF-β observed (Fig. 4b). The
release of TNF-α was not further reduced by treatment
with CM and MVs. These results suggest that CM and
MVs somehow act by interfering with the cellular re-
sponse to TGF-β, preventing its pro-inflammatory effect.
Discussion
Recent research focuses on strategies that allow func-
tional restoration of damaged tissue by cell-free ap-
proaches using CM or MVs. Accordingly, this study was
designed to investigate the in vitro immunomodulatory
effects of CM and MVs on LPS-induced cytokine pro-
duction in equine AMs, which may be beneficial in lung
inflammatory disorders, including RAO. Results ob-
tained are supportive of a potential use of CM and MVs
in lung regenerative medicine, especially in situations in
which TGF-β may be detrimental such as respiratory
allergy. Both CM and MVs significantly reduced LPS-
induced TNF-α production, together with a trend to
reduction in LPS-induced TGF-β and possibly IL-6
release, with CM acting faster when compared to MVs.
The latter result is consistent with the mode of action of
Table 1 Total and differential cell counts of bronchoalveolar
lavage.
Bronchoalveolar lavage (%)*
Macrophages (%) 58.4 ± 6.2
Lymphocytes (%) 22.8 ± 3.2
Neutrophils (%) 16.2 ± 4.8
Mast cells (%) 1.2 ± 1.3
Eosinophils (%) 1.4 ± 1.9
Total cell count (cells/μL) 460 ± 21.2
*Results are the mean of five samples ± SEM
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MVs, which requires internalization, modification of gene
transcription, and translation [28, 29], resulting in a
delayed effect compared to CM.
It was demonstrated that AMCs secrete MVs that were
able to counteract in vitro LPS-induced inflammation in
tendon cells by downregulation of MMP1, MMP9,
Fig. 2 Time-course and dose-response of lipopolysaccharide (LPS)-induced cytokine production. Alveolar macrophages were seeded at 2 × 106/
mL and, after adherence, treated for 1, 24, 48, and 72 h in the presence or absence of LPS (10 and 100 ng/mL). The release of tumor necrosis factor
alpha (TNF-α), interleukin-6 (IL-6), and transforming growth factor beta (TGF-β) were evaluated in conditioned medium by ELISA. Results are the mean
of a minimum of four experiments ± SEM. Statistical analysis was performed by Tukey’s multiple comparison test, with *p < 0.05 versus control cells
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MMP13, and TNFα expression [19]. This may support
the therapeutic in vivo administration of CM for the
treatment of spontaneous equine tendon injuries [11] as
the cargo and soluble factors of MVs could have contrib-
uted to the regenerative effect observed. MVs have been
implicated in a broad, and still largely uncharacterized,
range of physiological functions, such as immunity [30],
signaling [28], angiogenesis, extracellular matrix (ECM)
remodeling [31], and even gene regulation [32], which
may also be of interest for tissue engineering. Implica-
tion of MVs in a high number of physiological functions
makes them good candidates for the development of
new cell-free therapies.
As TGF-β is dominantly viewed as an immune sup-
pressive cytokine, the easiest explanation for the anti-
inflammatory effects observed could have been an in-
crease in its release by CM and MVs. However, this was
not the case. On the contrary, the neutralization of
TGF-β resulted in a marked reduction in LPS-induced
TNF-α release, which was not due to cytotoxicity as
assessed by MTT reduction, but most likely to a pro-
inflammatory effect of TGF-β, supported by the ability
of TGF-β alone to induce TNF-α release. TGF-β can in-
deed have multiple effects, resulting in both immuno-
suppression and immune-stimulation [33]. Our results
indicate a pro-inflammatory effect in equine AMs and
emphasizes the importance of the cellular and environ-
mental context in directing the discrete role of TGF-β.
Macrophages possess unique plasticity that provides
them with the ability to repair or to destroy. The repair
activity is commonly associated with M2 and the de-
structive activity with M1 macrophages. M1 and M2
were originally defined in vivo by the preferential pro-
duction of the causative functional molecules nitric
oxide or ornithine, which inhibit or promote prolifera-
tion, respectively. By sensing whether to exhibit repair
or destructive activities, macrophages are able to protect
individuals in ways best suited to correcting non-
infectious or infectious threats to hosts [34]. Their activ-
ity precedes the activation of specific immune responses
and, upon encounters with M1 or M2 macrophages,
other leukocytes are also induced to polarize, i.e., Th1-
or Th2-types, which are characterized by the preferential
production of cytokines such as IFN-γ or IL-4 that, in
turn, stimulate cytotoxic T and natural killer cells, or B
cells and antibody production, respectively. The clinical
impact of M1 and M2 responses is therefore immense,
having roles in curing or causing many diseases, includ-
ing infections, cancer, autoimmunity, allergy, and athero-
sclerosis [34].
A predominantly M2 phenotype in equine AMs has
been previously reported [35, 36]. This was also apparent
in the cytokine profile we observed. While having a role
in suppressing spontaneous inflammation in the lung,
Fig. 3 Effects of CM and MVs on the production of pro- and
anti-inflammatory cytokines. Alveolar macrophages were seeded
at 2 × 106/mL and, after adherence, treated for 1, 24, 48, and
72 h in the presence or absence of lipopolysaccharide (LPS) (10
and 100 ng/mL) or of conditioned medium (cond. medium) or
microvesicles. The release of tumor necrosis factor alpha (TNF-α),
interleukin-6 (IL-6), and transforming growth factor beta (TGF-β) were
evaluated in conditioned medium by ELISA. Results are the mean of a
minimum of three experiments ± SEM. Statistical analysis was performed
by Tukey’s multiple comparison test, with §p< 0.05 vs LPS-treated cells
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minimizing collateral tissue damage in a delicate tissue
variably exposed to pro-inflammatory agents [37], TGF-
β can have a detrimental effect in lung asthmatic reac-
tions [34] by favoring Th2 responses and B cell antibody
production. The ability of CM and MVs to contrast LPS-
induced cytokine production, including TGF-β, may be
beneficial in those diseases in which M2 are pathogenic.
Therefore, if one has allergy, one would wish to decrease
intra-lung M2-type and increase M1-type macrophages.
The cytotoxicity observed in AMs treated with TGF-β is
consistent with other studies reporting the ability of TGF-
β to induce apoptosis in various cell lines, particularly
immune-related cells [38–41]. Even if we only used MTT
reduction to assess cell viability, which does not allow us
to draw any conclusions on the type of cell death (and fur-
ther studies are necessary to address this point), literature
evidence is supportive of apoptosis where TGF-β has been
shown to regulate the mitochondria-dependent apoptotic
cascade in macrophages [42, 43].
Conclusion
Overall, results obtained showing the ability of CM and
MVs to modulate equine alveolar macrophages/innate im-
munity are paving the way to clinical applications in equine
lung diseases, such as RAO, and possibly other inflamma-
tory disorders such as inflammatory airway disease (IAD)
and exercise-induced pulmonary hemorrhage (EIPH).
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